Grupo Español de Tratamiento de Tumores Digestivos
LightNews LightNews
banner
ttdgroup.bsky.social
Grupo Español de Tratamiento de Tumores Digestivos
@ttdgroup.bsky.social
4 followers 12 following 130 posts
TTD Group-Grupo Español de Tratamiento de los Tumores Digestivos. Fomentamos la investigación clínica, traslacional y epidemiológica de los cánceres digestivos. www.ttdgroup.org
Posts Replies Media Videos
Pinned
ttdgroup.bsky.social
Grupo Español de Tratamiento de Tumores Digestivos @ttdgroup.bsky.social · Jul 21
📢SAVE THE DATE ‼

👉33 @GrupoTTD International Symposium

📅10-11-12 Dec. 2025
Oviedo (Spain)

🗣️A meeting point for leading specialists who will present the latest data related to the progress in the investigation of the digestive tumours

#TTD25

www.ttdgroup.org/formacion/si...
ttdgroup.bsky.social
📍Oncólogos y pacientes de cáncer gástrico reclaman desde el Senado un acceso "➕rápido y equitativo" a tratamientos innovadores contra este tipo de tumor

"El cáncer gástrico es un problema de salud enorme" afirma el Dr. Fernando Rivera, pdte. del TTD

www.infosalus.com/asistencia/n...
November 27, 2025 at 3:41 PM
ttdgroup.bsky.social
📍INTERACT-ION (phase II, stage III SCAC): Ezabenlimab + mDCF → adaptive chemoradiotherapy
👉 https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00605-9/fulltext?rss=yes 
✅cCR at 40 wks: 77.8% (INRT 86.8% vs CRT 69.2%)
✅PFS 24m: 81%, OS 24m: 84%

🧵(1/2)
⤵️
Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trial
Our study met the primary endpoint, showing antitumour activity (clinical complete response rates) and a manageable safety profile for ezabenlimab and mDCF induction when given with INRT in patients with locally advanced SCAC, enabling personalised INRT, and supporting phase 3 trials of this treatme...
www.thelancet.com
November 27, 2025 at 8:02 AM
ttdgroup.bsky.social
📍Día Int. contra el Cáncer Gástrico y Gastrectomizados

👉El TTD participa mañana en una acción divulgativa en el Senado, organizada por la Asociación contra el Cáncer Gástrico y Gastrectomizados

✍:https://docs.google.com/forms/d/e/1FAIpQLSevaMwVbHYPO5DL7NoIH6P5SQco15NMUhM_KlB6SpKHPWnC5Q/viewform
November 26, 2025 at 2:26 PM
ttdgroup.bsky.social
📍TRYBECA-1 (phase III, 2L PDAC): eryaspase (RBC-encapsulated L-asparaginase)+chemo vs chemo alone
👉https://ascopubs.org/doi/10.1200/JCO-25-00872
✅OS: 7.7 vs 6.9 m (HR 0.88; NS)
✅PFS: 3.8 vs 3.6 m (NS)
✅ORR: 10.2% vs 6.8%
🧵(1/2)
⤵️
TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma
PURPOSEThis phase III (ClinicalTrials.gov identifier: NCT03665441) study evaluated eryaspase in combination with chemotherapy as second-line treatment in advanced pancreatic ductal adenocarcinoma (PDAC).PATIENTS AND METHODSTRYBECA-1 enrolled patients 18 ...
ascopubs.org
November 25, 2025 at 8:02 AM
ttdgroup.bsky.social
➡️Cáncer de páncreas y equidad: que el código postal no determine las oportunidades de cada paciente

Opinan los Dres. Jorge Adeva y Teresa Macarulla, coordinadores del grupo de trabajo Biliopancreático del TTD

Puedes leerlo en Isanidad⤵️
isanidad.com/351293/cance...
Medicina de precisión y diagnóstico temprano en cáncer de páncreas: clave para mejorar el pronóstico
La integración de la secuenciación tumoral NGS en la práctica clínica es clave para el diagnóstico y tratamiento personalizado del cáncer de páncreas, mejorando su pronóstico
isanidad.com
November 21, 2025 at 10:04 AM
ttdgroup.bsky.social
✳️Que el código postal no determine las oportunidades de cada paciente

👉Con motivo del DM #CáncerdePáncreas, J. Adeva y T. Macarulla opinan en El Periodico

🎯Medicina personalizada en todas las CCAAs

ℹ️https://www.elperiodico.com/es/opinion/20251120/cancer-pancreas-equidad-codigo-postal-123943264s
November 20, 2025 at 4:56 PM
ttdgroup.bsky.social
📍El cáncer de páncreas es uno de los tumores más agresivos y con menos tratamientos disponibles.

El TTD investiga para avanzar en nuevas terapias que mejoren la calidad de vida de los pacientes.

Nº de estudios: 10🧪

Datos de➕3600 pacientes del TTD RETUD

#SomosTTD
November 20, 2025 at 12:02 PM
ttdgroup.bsky.social
📍No te pierdas la XI Carrera de las Ciudades contra el cáncer de páncreas🏃‍♀️

Un año más, el GrupoTTD se suma como patrocinador en Madrid.

📆Próximas citas
23 NOV/ALICANTE
23 NOV/MADRID
23 NOV/ORENSE
30 NOV/AVILA
CARRERA VIRTUAL DEL 10 AL 23 DE NOV🏃‍♀️

ℹ️https://carreracancerpancreas.es
November 18, 2025 at 11:19 AM
ttdgroup.bsky.social
📍Estudio GENERATE (JCOG1611). Estudio comparativo en cáncer de páncreas metastásico en 1ªlínea de tratamiento
https://ascopubs.org/doi/10.1200/JCO.24.00936

👉Estudio comparativo MFOLFIRINOX, S-IROX y nab-paclitaxel-gemcitabina

(🧵1/2)
Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurrent Pancreatic Cancer (GENERATE, JCOG1611): A Randomized, Open-Label, Phase II/III Trial
PURPOSEModified fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX) and nab-paclitaxel + gemcitabine are recommended as first-line treatments for metastatic pancreatic cancer. S-1, irinotecan, and oxaliplatin (S-IROX) demonstrated activity ...
ascopubs.org
November 11, 2025 at 8:02 AM
ttdgroup.bsky.social
📍Perioperative camrelizumab➕rivoceranib vs surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial
🔗https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01720-9/abstract
🧵(1/3)
#TTDUpdates
⤵️
Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial
Perioperative camrelizumab plus rivoceranib significantly improved EFS compared with surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence.
www.thelancet.com
November 10, 2025 at 3:04 PM
ttdgroup.bsky.social
📍Cáncer de hígado: el reto pendiente en el tumor 'silencioso'

Compartimos el artículo de opinión del Dr. Fernando Rivera (presidente del TTD y jefe del servicio de oncología médica de HU Marqués de Valdecilla) en ABC con motivo del #Díamundialcancerhígado

www.abc.es/salud/enferm...
October 30, 2025 at 2:40 PM
ttdgroup.bsky.social
📍#DíaMundialCáncerHígado

El TTD recuerda que prevención, detección precoz e investigación cooperativa son esenciales para salvar vidas🔬

👉Los ensayos multicéntricos coordinados permiten avanzar hacia tratamientos➕personalizados

✍️https://efesalud.com/cancer-higado-ensayos-investigacion-dia-mundial
October 30, 2025 at 8:40 AM
ttdgroup.bsky.social
📍No te pierdas el #TTDCOLOQUIO Novedades en terapias dirigidas en CCRm
📅25NOV
⏰17h
Coordina: Dra Rith Vera
📢Dres. F. Salvà (VHebron)
J. Alcaide(HUR Málaga)
J. Sastre(HUC San Carlos)
https://www.ttdgroup.org/contenidos/formacion/workshop/evento.aspx
Patrocina Merck👉Abierto a especialistas interesados
October 27, 2025 at 6:30 PM
ttdgroup.bsky.social
📍Pembrolizumab + Chemotherapy as Perioperative Therapy in Resectable Gastric & GEJ Cancer
https://ascopubs.org/doi/10.1200/JCO-25-00486 
Phase III, randomized trial (n = 1,007)
✅ Design:Neoadjuvant + adjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy ✅ Median follow-up:59.9 months
Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study
We report results of the final analysis of overall survival (OS) and patient-reported outcomes from the phase III KEYNOTE-585 (ClinicalTrials.gov identifier: NCT03221426) study. Participants with previously untreated, locally advanced, resectable gastric ...
ascopubs.org
October 27, 2025 at 8:03 AM
ttdgroup.bsky.social
TTD JOURNAL CLUB-Investigación de vanguardia en tumores digestivos
👉#ESMO25
📢Escucha a la Dra. Ana Mª López con las últimas novedades en:
📽️BILIOPANCREÁTICOS https://lnkd.in/d574m8Jn
📽️HEPATOCARCINOMA https://lnkd.in/deTNgH_y
📽️HEPAT. estado intermedio https://lnkd.in/dj8Bb8d5
October 24, 2025 at 8:03 AM
ttdgroup.bsky.social
TTD JOURNAL CLUB-Investigación de vanguardia en tumores digestivos
👉TTD-#ESMO25. CÁNCER ESOFAGOGÁSTRICO
📢Escucha a la Dra. Mireia Gil destacando las últimas novedades.
📽️Adenocarcinoma gástrico vimeo.com/showcase/119...
📽️Carcinoma Escamoso Esófago vimeo.com/showcase/119...
October 23, 2025 at 11:03 AM
ttdgroup.bsky.social
📍Neoadjuvant CTLA-4/PD-(L)1 Blockade in Resectable dMMR/MSI-High Gastroesophageal Adenocarcinoma https://pubmed.ncbi.nlm.nih.gov/41021880
Pooled individual patient-level analysis (n=197 patients)
✅ICIs→higher pCR(61.9%vs3.7%)&MPR(78.6%vs10%) vsFLOT
✅Lower ypN+(14%vs37%)&ypT(OR 16.4;p<001)
⬇️
Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/- Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability-High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled Analysis - PubMed
In resectable dMMR/MSI-H GEA, neoadjuvant ICIs significantly increase pathologic response and downstaging versus FLOT, with comparable EFS/OS with surgery with or without chemotherapy. The higher proportion of ypN0 and lack of ypT4 after neoadjuvant ICIs versus FLOT should drive preoperative treatme …
pubmed.ncbi.nlm.nih.gov
October 23, 2025 at 7:03 AM
ttdgroup.bsky.social
📍Checkpoint inhibitor benefit in perioperative gastro-esophageal cancer
https://pubmed.ncbi.nlm.nih.gov/40779895
Meta-analysis of phase3⃣trials(MATTERHORN&KEYNOTE-585)
✅FLOT+IO>Cis/5FU+IO for EFS (HR 0.79; p=0.021)
👉IO+FLOT emerges as standard-of-care candidate in resectable GE adenocarcinoma
October 22, 2025 at 10:04 AM
ttdgroup.bsky.social
📍CHALLENGE
https://pubmed.ncbi.nlm.nih.gov/40450658/
👉Ensayo fase 3
👉Ejercicio estructurado 3 años post-QT adyuvante en cáncer colon resecado
↑ supervivencia libre enfermedad (HR 0,72; p=0,02) y ↑ SG a 8 años (90,3% vs 83,2%)
👉Evidencia nivel 1 del beneficio oncológico del ejercicio
Structured Exercise after Adjuvant Chemotherapy for Colon Cancer - PubMed
A 3-year structured exercise program initiated soon after adjuvant chemotherapy for colon cancer resulted in significantly longer disease-free survival and findings consistent with longer overall survival. (Funded by the Canadian Cancer Society and others; CHALLENGE ClinicalTrials.gov number, NCT008 …
pubmed.ncbi.nlm.nih.gov
October 17, 2025 at 3:03 PM
ttdgroup.bsky.social
📍The CANOPTIPHYS randomised controlled trial
https://pubmed.ncbi.nlm.nih.gov/40450796
Ensayo en ≥65 años con CCR:ejercicio preoperatorio (2-3 sem) vs cuidados estándar
👉No⬇️complicaciones postoperatorias(48,1% vs62,5%)
👉Mostró tendencia➕en recuperación y viabilidad del programa domiciliario
Effect of preoperative exercise on postoperative complications after colorectal cancer surgery in older people with low physical fitness: The CANOPTIPHYS randomised controlled trial - PubMed
In this study of older patients with low physical fitness awaiting colorectal cancer surgery, we could not demonstrate an influence of preoperative exercise on postoperative complications, discharge destination or length of hospital stay. These results should be interpreted with caution due to a sma …
pubmed.ncbi.nlm.nih.gov
October 16, 2025 at 3:03 PM
ttdgroup.bsky.social
📍Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer
https://pubmed.ncbi.nlm.nih.gov/36610262 
➡️Estudio retrospectivo que analiza la prevalencia de expresión de CLDN18.2“. 
(🧵1/2)
Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer - PubMed
CLDN18.2 expression in advanced GC/GEJC was associated with some clinical and molecular features but had no impact on treatment outcomes with chemotherapy or checkpoint inhibition. CLDN18.2-positive also had no impact on overall survival. This information could be useful to interpret the results fro …
pubmed.ncbi.nlm.nih.gov
October 15, 2025 at 3:03 PM
ttdgroup.bsky.social
📍Clinical characterization of FGFR2b expression in patients with advanced gastric or gastroesophageal junction adenocarcinoma
https://pubmed.ncbi.nlm.nih.gov/40513139/ 
➡️FGFR2b identifica un subgrupo molecular independiente en cáncer gástrico avanzado con una potencial terapia dirigida
(🧵1/2)
Clinical characterization of FGFR2b expression in patients with advanced gastric or gastroesophageal junction adenocarcinoma - PubMed
This study revealed limited overlap of FGFR2b overexpression with currently actionable biomarkers, suggesting FGFR2b is a novel biomarker that identifies a distinct GC/GEJC patient population who may benefit most from an FGFR2b-targeting therapy.
pubmed.ncbi.nlm.nih.gov
October 14, 2025 at 3:04 PM
ttdgroup.bsky.social
📍Enrique Aranda, jefe de Oncología Médica de H.U. Reina Sofia:"Los programas de cribado de cáncer salvan muchas vidas"

El expresidente del TTD, referente en tumores digestivos, acaba de ser reconocido con un premio a su trayectoria clínica y científica👏👏

www.diariocordoba.com/cordoba-ciud...
El cordobés Enrique Aranda, jefe de Oncología Médica del hospital Reina Sofía: 'Los programas de cribado de cáncer salvan muchas vidas'
Este doctor, referente nacional en tumores digestivos, acaba de ser reconocido con un premio a su trayectoria clínica y científica
www.diariocordoba.com
October 14, 2025 at 7:27 AM
ttdgroup.bsky.social
📍XI Carrera de las Ciudades contra el cáncer de páncreas🏃‍♀️
Un año más, el Grupo TTD se suma como patrocinador en Madrid.

📆
16 NOV/VALENCIA
16 NOV/BURGOS
23 NOV/ALICANTE
23 NOV/MADRID
23 NOV/ORENSE
30 NOV/AVILA
CARRERA VIRTUAL DEL 10 AL 23 DE NOV🏃‍♀️

ℹ️https://carreracancerpancreas.es
October 13, 2025 at 8:28 AM
ttdgroup.bsky.social
📍JNCI 2025: Early-onset CRC(<50y) rising in 🇦🇺🇨🇦🇬🇧🇺🇸
✅Risk 5–7x higher in 1990vs1960 cohorts
✅Annual↑~8.5%(20–39y), up to10–11%in women

#CRC 
(1/2)🧵
October 3, 2025 at 7:02 AM